SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, Van Weel C, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary. Am J Respir Crit Care Med 2007; 176: 53255.
  • 2
    Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004; 364: 70921.
  • 3
    Hogg JC, Chu F, Utokaparch S, Wood R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Paré PD. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 264553.
  • 4
    Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 297304.
  • 5
    Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998; 50: 27990.
  • 6
    Coulson FR, Fryer AD. Muscarinic acetylcholine receptors and airway diseases. Pharmacol Ther 2003; 98: 5969.
  • 7
    Gross NJ, Co E, Skorodin MS. Cholinergic bronchomotor tone in COPD: estimates of its amount in comparison to that in normal subjects. Chest 1989; 96: 9847.
  • 8
    Nisar M, Earis JE, Pearson MG, Calverley PM. Acute bronchodilator trials in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 146: 5559.
  • 9
    Gross NJ. Ipratropium bromide. N Engl J Med 1988; 319: 48694.
  • 10
    Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T Jr. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 21724.
  • 11
    Gross NJ. Tiotropium bromide. Chest 2004; 126: 194653.
  • 12
    Engstrom CP, Persson LO, Larsson S, Ryden A, Sullivan M. Functional status and well being in chronic obstructive pulmonary disease with regard to clinical parameters and smoking: a descriptive and comparative study. Thorax 1996; 51: 82530.
  • 13
    Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997; 349: 1498504.
  • 14
    Gavaldà A, Miralpeix M, Ramos I, Vilella D, Sentellas S, Alberti J, Ryder H, Beleta J. Aclidinium bromide, a novel muscarinic receptor combining long residence at M3 receptors and rapid plasma clearance. Eur Respir J 2007; 30 (Suppl. 51): 209S210S.
  • 15
    Joos GF, Schelfhout VJ, Kanniess F, Ludwig-Sengpill A, Garcia Gil E, Montejo EM. Bronchodilator effects of aclidinium bromide, a novel long-acting anticholinergic, in COPD patients: a Phase II study. Eur Respir J 2007; 30 (Suppl. 51): 210S.
  • 16
    Almirall Internal Document. Four-week inhalation toxicity study in dogs. 1900; RCC 780388.
  • 17
    Almirall Internal Document. Four-week inhalation toxicity study in rats. 1900; RCC 780772.
  • 18
    Dubois AB, Botheho SY, Bedell GN, Marshall R, Comroe JH. A rapid plethysmographic method for measuring thoracic gas volume: a comparison with a nitrogen washout method for measuring functional residual capacity in normal subjects. J Clin Invest 1956; 35: 3226.
  • 19
    Dubois AB, Botheho SY, Comroe JH. A new method for measuring airway resistance in man using a body plethysmograph: values in normal subjects and in patients with respiratory disease. J Clin Invest 1957; 35: 32734.
  • 20
    Crapo R, Casaburi R, Coates A, Enright PL, Hankinson JL, Irvin CG, MacIntyre NR, McKay RT, Wanger JS, Anderson SD, Cockcroft DW, Fish JE, Sterk PJ. Guidelines for methacholine and exercise challenge testing-1999. Am J Respir Crit Care Med 2000; 161: 30929.
  • 21
    Houghton CM, Woodcock AA, Singh D. A comparison of plethysmography, spirometry and oscillometry for assessing the pulmonary effects of inhaled ipratropium bromide in healthy subjects and patients with asthma. Br J Clin Pharmacol 2005; 59: 1529.
  • 22
    Joos GF, Pauwels RA, Van der Straeten ME. The effect of nedocromil sodium on the bronchoconstrictor effect of neurokinin A in subjects with asthma. J Allergy Clin Immunol 1989; 83: 6638.
  • 23
    Abrams P, Andersson KE, Buccafusco JJ, Chapple C, De Groat WC, Fryer AD, Kay G, Laties A, Nathanson NM, Pasricha PJ, Wein AJ. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006; 148: 56578.